Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

439
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
439
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

700
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
700
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Gene-Gene Interaction Between Factor-<i>XI</i> and <i>ABO</i> Genes in Cerebral Venous Thrombosis: The BEAST Study.

Neurology·2024
Same author

Prediction of venous thromboembolism in average-risk, young candidates for oral contraceptive use: to genotype, or not to genotype, that is the question.

American journal of obstetrics and gynecology·2024
Same author

Coma in adult cerebral venous thrombosis: The BEAST study.

European journal of neurology·2024
Same author

Post-lumbar puncture cerebral vein thrombosis.

EJHaem·2024
Same author

Genetic Variants Identified by Whole Exome Sequencing in a Large Italian Family with High Plasma Levels of Factor VIII and Von Willebrand Factor.

International journal of molecular sciences·2023

Related Experiment Video

Updated: Apr 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Uncertain thrombophilia markers.

Massimo Franchini, Ida Martinelli, Pier Mannuccio Mannucci1

  • 1Pier Mannuccio Mannucci, MD, Via Pace 9, 20122 Milano, Italy, Tel.: +39 02 55038377, Fax: +39 02 50320723,

Thrombosis and Haemostasis
|August 15, 2015
PubMed
Summary
This summary is machine-generated.

Inherited and acquired risk factors for venous thromboembolism (VTE) are identified through plasma and DNA testing. This review discusses established and uncertain thrombophilia causes, recommending against routine testing for less consistent factors.

Keywords:
Thrombophiliathrombophilia markersvenous thromboembolism

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

106
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.4K

Related Experiment Videos

Last Updated: Apr 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

106
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.4K

Area of Science:

  • Hematology
  • Genetics
  • Clinical Pathology

Background:

  • Venous thromboembolism (VTE), encompassing deep-vein thrombosis and pulmonary embolism, is linked to inherited and acquired risk factors.
  • Established thrombophilias include deficiencies in antithrombin, protein C, and S, factor V Leiden, prothrombin G20210A mutations, dysfibrinogenaemias, and elevated factor VIII levels.

Purpose of the Study:

  • To review uncertain causes of thrombophilia and their clinical impact.
  • To discuss the pathogenetic mechanisms underlying less consistently associated VTE risk factors.
  • To evaluate the current evidence for including these uncertain factors in routine thrombophilia screening.

Main Methods:

  • Narrative review of existing literature.
  • Analysis of clinical impact and pathogenetic mechanisms of various thrombophilia markers.
  • Evaluation of current diagnostic guidelines and recommendations for thrombophilia testing.

Main Results:

  • Established thrombophilia biomarkers are crucial for initial screening.
  • Several additional abnormalities show inconsistent association with VTE risk.
  • Insufficient evidence currently supports routine testing for these less consistent thrombophilia markers.

Conclusions:

  • Established thrombophilia testing remains the standard of care.
  • Further research is needed to clarify the clinical utility of less common thrombophilia markers.
  • Current guidelines do not support the inclusion of uncertain thrombophilia causes in routine VTE risk assessment.